Just in time for Christmas, NIH Director Francis Collins has approved more human embryonic stem cell lines for taxpayer funding, bringing the total number of hESC lines at the federal trough to 142.
NIH Director Francis Collins has approved another human embryonic stem cell line for federal taxpayer funding. The line, HUES PGD 14, was added to the NIH registry today, bringing the total number of approved hESC lines to 136.
Yesterday NIH Director Francis Collins approved three more human embryonic stem cell lines for taxpayer funding, bringing the total to 135.
An Israeli company is conducting a clinical trial using a patient’s own adult stem cells to treat ALS (Lou Gehrig’s disease.) The method using adult stem cells was developed by professors at Tel Aviv University. Cells are taken from a patient’s own bone marrow and differentiated in the lab into astrocytes, cells responsible for nurturing neurons in the brain. By releasing neurotrophic factors, which are proteins that can protect brain cells, the former bone marrow adult stem cells can protect and preserve brain cell function.
Prof. Dr. med. Bodo-Eckehard Strauer did his first clinical treatment using adult stem cell transplant for a heart patient on March 30, 2001, over ten years ago. Since that time, he and his team have treated hundreds of patients, have published a text on such heart treatments, and many other groups around the world have used adult stem cells for treatment of heart disease.
Scientists at the University of Wisconsin-Madison have used detailed, high-tech analysis to examine the differences between human embryonic stem cells (ESC) and induced pluripotent stem cells (iPSC).